|
Re: early report imo
|
4
|
Resverlogix Corp.
|
Jul 02, 2022 03:44PM
|
|
Re: Warning: Long - Thoughts on Management
|
4
|
Resverlogix Corp.
|
Mar 25, 2021 07:18PM
|
|
Re: Gilead pays $21B for Immunomedics, a single cancer drug (newly approved) for metastic Triple Negative Breast Cancer
|
4
|
Zenith Epigenetics
|
Sep 22, 2020 07:55PM
|
|
Re: Another IPO that shocks!
|
4
|
Zenith Epigenetics
|
Jan 16, 2021 08:19AM
|
|
Re: More Exempt Distribution Investments
|
4
|
Zenith Epigenetics
|
Feb 29, 2024 10:38AM
|
|
Re: Saudi
|
4
|
Resverlogix Corp.
|
Jan 16, 2021 08:55AM
|
|
Re: Pfizer seems like a good fit for a BP deal
|
4
|
Zenith Epigenetics
|
Jan 09, 2024 02:52PM
|
|
Re: 2 year extension
|
4
|
Resverlogix Corp.
|
May 14, 2024 07:53PM
|
|
Re: Nasdaq!!
|
4
|
Resverlogix Corp.
|
Feb 05, 2019 05:45PM
|
|
Re: RESVERLOGIX ANNOUNCES VOTING RESULTS FROM THE 2022 MEETING OF SHAREHOLDERS
|
4
|
Resverlogix Corp.
|
Jun 23, 2022 02:51AM
|
|
Re: Zenith Epigenetics Announces U.S. FDA Clearance of Investigational New Drug Application for ZEN-3694 in TNBC Program
|
4
|
Zenith Epigenetics
|
Mar 18, 2019 02:39PM
|
|
Re: Zenith Epigenetics Proudly Supports Rare Disease Day ZEN-3694 Expands Development to Include Multiple Rare Oncology Indications Calgary, Alberta--(N
|
4
|
Zenith Epigenetics
|
Feb 29, 2024 11:09AM
|
|
Re: All quiet on the western front
|
4
|
Resverlogix Corp.
|
Jan 07, 2021 03:16PM
|
|
Re: Wikipedia on Investor Relations: Goal is Fair Valuation
|
4
|
Zenith Epigenetics
|
May 27, 2016 05:16PM
|
|
Re: "...quite remarkable... 1 year experiment of age reversing with epigenetics..."
|
4
|
Resverlogix Corp.
|
Feb 06, 2023 04:01PM
|
|
Re: Nasdaq listing -- Awesome News!!
|
4
|
Resverlogix Corp.
|
Aug 01, 2018 05:43AM
|
|
No data, No communication,,no interest!!
|
4
|
Zenith Epigenetics
|
Dec 29, 2023 09:25AM
|
|
Re: Saudi
|
4
|
Resverlogix Corp.
|
Jan 16, 2021 09:58AM
|
|
Re: Shorts
|
4
|
Resverlogix Corp.
|
Jun 09, 2018 08:03AM
|
|
Re: Recap / webcast / blackout...
|
4
|
Resverlogix Corp.
|
Feb 28, 2016 09:33PM
|
